Comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

Comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

A team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted a head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. It is the first study to analyze two new drugs, lorlatinib and brigatinib, outside of clinical trials. The findings…

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

In the largest real-world analysis of U.S. patients, researchers used insurance claims data to study the effectiveness of five drugs known as tyrosine kinase inhibitors to better understand differences in how the drugs affect patient outcomes. The post USC comparison study of leading targeted therapies for a specific lung cancer could lead to better treatment decisions appeared first on USC.